(MENAFN Editorial) iCrowdNewswire – Aug 7, 2018
Global Pulmonary Arterial Hypertension (PAH) Market : Industry Analysis and Outlook (2018-2022) Report provides an extensive research on the fast-evolving Pulmonary Arterial Hypertension (PAH) Market. It also gives competitive landscape of the leading companies with regional and global analysis of the market till 2022.
Pulmonary arterial hypertension (PAH) is one form of pulmonary hypertension (PH) condition, which means high blood pressure in the lungs. Many diseases such as obstructive sleep apnea (OSA), lung diseases, diastolic heart failure and diseases of the left heart can cause the pressures in the pulmonary arteries to elevate but is not pulmonary arterial hypertension. PAH is a life threatening disease characterized by an increase in pulmonary vascular resistance that eventually leads to death. It is a rare disease, affects about 15-70 people per million in the U.S. The symptoms of PAH are difficult to diagnose as the symptoms are common to other diseases.
Get Sample PDF of the Report @ http://www.orbisresearch.com/contacts/request-sample/2274234?utm_source=sru
The report profiles the key players in the market including